Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.
Also called NCT06772168
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- CMG Pharmaceutical Co. Ltd
- Registry
-
NCT06772168
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06772168. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2026-11-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
- Condition
- Dyslipidemia
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- CMG190303(Dapagliflozin/Rosuvastatin)
- Intervention (Drug)
- Comparator 1: Dapagliflozin/Rosuvastatin placebo
- Intervention (Drug)
- Rosuvastatin/Dapagliflozin placebo
- Lead sponsor
- CMG Pharmaceutical Co. Ltd
Record details
- Record id
cardio:ct-nct06772168- Content hash
3ca5675b8d938d7a79146c02414a207caf5726fbe0eb12649c643832ad706801